---
title: Use of Medium Frequency Electrotherapy in the Treatment of OAB, LUTS and Pelvic Pain
nct_id: NCT03520166
overall_status: COMPLETED
phase: NA
sponsor: Fisioterapia Pélvica Avanzada Madrid, SRL
study_type: INTERVENTIONAL
primary_condition: Urinary Bladder, Overactive
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03520166.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03520166"
ct_last_update_post_date: 2018-05-09
last_seen_at: "2026-05-12T07:08:13.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Use of Medium Frequency Electrotherapy in the Treatment of OAB, LUTS and Pelvic Pain

**Official Title:** Treatment of Overactive Bladder, Lower Urinary Tract Symptoms and Pelvic Pain With Medium Frequency Electrotherapy (Interferential Currents)

**NCT ID:** [NCT03520166](https://clinicaltrials.gov/study/NCT03520166)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 100
- **Lead Sponsor:** Fisioterapia Pélvica Avanzada Madrid, SRL
- **Conditions:** Urinary Bladder, Overactive, Lower Urinary Tract Symptoms, Pelvic Pain
- **Start Date:** 2014-01-10
- **Completion Date:** 2017-06-30
- **CT.gov Last Update:** 2018-05-09

## Brief Summary

The aim of this study is to assess the effectiveness of medium frequency electrotherapy (interferential currents) treatment for overactive bladder (OAB), lower urinary tract symptoms (LUTS) and pelvic pain

## Detailed Description

This study consists of 100 women, complaining of increased bladder sensation and urgency with or without incontinence as principal symptomatology and who had not received previous pharmacological treatment. Group-A was used as a control group (n = 50). Group-B patients received 18 sessions of medium frequency electrotherapy during 9 weeks, 2 weekly sessions

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

Increased bladder sensation Urgency Overactive bladder Lower urinary tract symptoms Pelvic pain

Exclusion Criteria:

Neurogenic bladder Acute urinary infection Pelvic floor surgery Congenital urological malformations Age less than 18 years Bladder organic pathology Pelvic radiotherapy
```

## Arms

- **Group-A** (PLACEBO_COMPARATOR) — No treatment
- **Group-B** (EXPERIMENTAL) — Medium frequency electrotherapy (interferential currents)

## Interventions

- **Medium frequency electrotherapy (interferential currents)** (OTHER) — Treatment with medium frequency electrotherapy, interferential currents between 5500 Hz and 8500 Hz (Combi-200®, Gymna®), was performed using transvaginal application. The frequency was increased progressively over the first six sessions (twice a week), starting with a frequency of 5500 Hz until reaching a frequency of 8500 Hz, which remained until the end of treatment.
- **No treatment** (OTHER) — No treatment

## Primary Outcomes

- **urgency** _(time frame: 24 hours)_ — with or without urge incontinence, usually with frequency and nocturia, can be described as the overactive bladder syndrome, urge syndrome or urgency-frequency syndrome. Measured with 24 hour voiding diary.

## Secondary Outcomes

- **urge urinary incontinence** _(time frame: 24 hours)_
- **increased daytime frequency** _(time frame: 24 hours)_
- **nocturia** _(time frame: 24 hours)_
- **increased bladder sensation** _(time frame: 24 hours)_
- **feeling of incomplete emptying** _(time frame: 24 hours)_
- **nocturnal enuresis** _(time frame: 24 hours)_
- **incontinence** _(time frame: 24 hours)_
- **pelvic pain** _(time frame: 24 hours)_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03520166.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03520166*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*